A novel anti-CD3xCD28xSTEAP1 trispecific T-cell engager (HLX3902) with enhanced and durable antitumor responses in prostate cancer
科学论文
Efficacy and Safety of Integrating Consolidative Thoracic Radiotherapy with Immunochemotherapy in ES-SCLC: A Real-world Retrospective Analysis
ESMO 2024
Consolidation Serplulimab Following Concurrent Hypofractionated Chemoradiotherapy for Limited-stage SCLC: Preliminary Analysis of Phase II ASTRUM-LC01 Study
ESMO 2024
"First-line serplulimab vs. placebo combined with chemotherapy for extensive-stage small-cell lung cancer: extended follow-up results and patient-
reported outcomes for the Asian population from the international phase 3 ASTRUM-005 study"
CSCO 2024
"A phase 3 study of serplulimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer: ASTRUM-004 Chinese subgroup"
